204 related articles for article (PubMed ID: 36401704)
1. Targeting the PI3K Pathway in Gynecologic Malignancies.
Avila M; Grinsfelder MO; Pham M; Westin SN
Curr Oncol Rep; 2022 Dec; 24(12):1669-1676. PubMed ID: 36401704
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
4. PI3K pathway in gynecologic malignancies.
Salvesen HB; Werner HM; Krakstad C
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714506
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):847-58. PubMed ID: 25301678
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Loi S; Michiels S; Baselga J; Bartlett JM; Singhal SK; Sabine VS; Sims AH; Sahmoud T; Dixon JM; Piccart MJ; Sotiriou C
PLoS One; 2013; 8(1):e53292. PubMed ID: 23301057
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Slomovitz BM; Filiaci VL; Walker JL; Taub MC; Finkelstein KA; Moroney JW; Fleury AC; Muller CY; Holman LL; Copeland LJ; Miller DS; Coleman RL
Gynecol Oncol; 2022 Mar; 164(3):481-491. PubMed ID: 35063278
[TBL] [Abstract][Full Text] [Related]
8. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.
Oda K; Ikeda Y; Kashiyama T; Miyasaka A; Inaba K; Fukuda T; Asada K; Sone K; Wada-Hiraike O; Kawana K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2016 Jul; 42(7):757-62. PubMed ID: 27094348
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
10. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
11. Emerging strategies for targeting PI3K in gynecologic cancer.
Bregar AJ; Growdon WB
Gynecol Oncol; 2016 Feb; 140(2):333-44. PubMed ID: 26432040
[TBL] [Abstract][Full Text] [Related]
12. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
14. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
[TBL] [Abstract][Full Text] [Related]
15. Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
Lu XY; Yang Y; Xu H; Zeng T; Zhang ZZ
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2264-9. PubMed ID: 25219824
[TBL] [Abstract][Full Text] [Related]
16. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Konstantinopoulos PA; Lee EK; Xiong N; Krasner C; Campos S; Kolin DL; Liu JF; Horowitz N; Wright AA; Bouberhan S; Penson RT; Yeku O; Bowes B; Needham H; Hayes M; Sawyer H; Polak M; Shea M; Cheng SC; Castro C; Matulonis UA
J Clin Oncol; 2023 Jan; 41(3):599-608. PubMed ID: 36174113
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
18. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
Song L; Liu S; Zhao S
Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
[TBL] [Abstract][Full Text] [Related]
19. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
20. A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.
de Melo AC; Paulino E; Garces ÁH
Oxid Med Cell Longev; 2017; 2017():4809751. PubMed ID: 28286604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
